Bringing effective new treatment options to patients who need them

 

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Find Out More

CLINICAL PIPELINE

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers.  Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours

Find Out More

 

PLATFORM TECHNOLOGIES

01

Allo CAR T Cell Therapy; azer-cel (azercabtagene zapreleucel) is an off-the-shelf (allogeneic) cell therapy CAR T drug which targets CD19 to treat blood cancers. It is currently in a Phase 1b trial dosing diffuse large B cell lymphoma (DLBCL) patients who have relapsed off autologous CAR T therapy.

Find Out More

02

onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour responses against solid tumours.

Find Out More

03

CF33 Oncolytic Virus; CF33, developed by Professor Yuman Fong, at the prestigious City of Hope Comprehensive Cancer Center in Los Angeles, California is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent oncolytic virus. Our CF33 (hNIS) gene, which enables imaging to track the virus in vivo is called VAXINA.

Find Out More

04

B-cell immunotherapies are cancer vaccines that vaccinate and induce the body to produce antibodies against validated oncology targets, such as HER2 (HER-Vaxx) or PD-1 (PD1-Vaxx).

Find Out More

Our Vision

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments.

This vision is backed by a growing body of clinical evidence and peer-reviewed research.

Find Out More

Investor Centre

Overview
Presentations
Financial Reports
Media

Latest ASX Announcements

View More

Follow Us

View More
Subscribe to our email newsletter to receive the latest news and updates
This field is for validation purposes and should be left unchanged.